Multi-omics molecular subgrouping of hepatocellular carcinoma and its application in precision diagnosis and treatment
10.3969/j.issn.1001-5256.2022.03.004
- VernacularTitle:肝细胞癌多组学分子分型及其在精准诊疗中的应用
- Author:
Liangqing DONG
1
;
Qiang GAO
1
Author Information
1. Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Publication Type:Discussions by Experts
- Keywords:
Carcinoma, Hepatocellular;
Genetic Heterogeneity;
Drug Screening Assays, Antitumor;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(3):510-514
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality in China. In recent years, the application of targeted therapy and immunotherapy has improved the survival rate of HCC patients. However, a significant difference in treatment response is observed among HCC patients due to tumor heterogeneity and a lack of biomarkers to predict efficacy. The advance in proteogenomics-centered multi-omics studies and the development of high-throughput drug screening platforms will help to develop new clinical treatment strategies for HCC and new methods for predicting the efficacy of precision medication, thereby realizing personalized precision diagnosis and treatment.
